Blood
Articles in this Issue
Therapy by omission: observation as a strategy in JMML
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Abstract Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) pa...
A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia
Abstract Immune thrombocytopenia (ITP) is characterized by the overproduction of antiplatelet autoantibodies. Although B-cell depletion therapies show promise in ITP, their high re...
Faulty antibody editing permits antiplatelet B cells in ITP
How I approach hematopoietic stem cell transplantation for CML in a TKI world
Abstract After the introduction of tyrosine kinase inhibitors (TKIs), the number of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic p...
High CTC, high-risk cytogenetics: a dangerous duo in MM?
Therapeutic base editing to generate a gain-of-function <i>F9</i> variant for hemophilia B
Abstract The repair of pathological gene variants is an ultimate goal in treating genetic diseases; however, developing distinct therapeutic reagents for each of the numerous varia...
How I treat chronic myeloid leukemia in children and adolescents
Abstract Chronic myeloid leukemia (CML) is rare in children and adolescents. Although outcomes have dramatically improved owing to tyrosine kinase inhibitors (TKIs) in the last 2 d...
The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort
Abstract Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive pediatric myeloproliferative neoplasm for which hematopoietic stem cell transplantation (HSCT) is currently t...
USP25-mediated talin-1 stabilization in platelets: a novel mechanism of hyperreactivity and thrombosis risk during aging
Abstract Aging is a critical risk factor for platelet hyperreactivity and thrombosis, yet the mechanisms involved remain poorly understood. This study investigates the role of ubiq...
TP53-mutated AML with salmon-colored globules, a single Auer rod, pseudo–Chédiak-Higashi granules, and micronuclei
Introduction to a How I Treat series on chronic myeloid leukemia
Associate Editor Jason Gotlib introduces a comprehensive How I Treat series on chronic myeloid leukemia (CML) that focuses on the multidimensional aspects of CML care. All articles in the series use c...
How I treat advanced phases of CML
Abstract Advanced phases of Philadelphia chromosome–positive chronic myeloid leukemia (CML), classically encompassing de novo presentation of accelerated-phase disease and blast-ph...
How I evaluate and treat resistance and relapse in CML
Abstract As evidenced by the excellent survival outcomes, chronic myeloid leukemia treatment in the era of tyrosine kinase inhibitors (TKIs) is often successful. However, when resp...
USP25 and platelet hyperreactivity in aging
How I manage chronic myeloid leukemia during pregnancy
Abstract Chronic myeloid leukemia (CML) represents a paradigm of success in targeted therapy, with tyrosine kinase inhibitors (TKIs) revolutionizing patient outcomes. This progress...
A Padua moment for factor VIII gene therapy
How I individualize frontline treatment for chronic-phase CML
Abstract Chronic myeloid leukemia (CML) has served as a paradigm for the development of effective initial and next-generation targeted therapies. The availability of 5 effective an...
Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy
Abstract The major challenges of gene therapy for hemophilia A using adeno-associated virus (AAV) vectors are reducing vector doses and the long-term maintenance of stable factor V...